NeuroRx: Developing first Glx targeted antidepressant to address suicidality in bipolar depression. Lead candidate, NRX-101 in Ph 2b/3 devt (Breakthru Designation, SPA and Fast Track Designation by FDA) for Severe Bipolar Depression in pts w Acute Suicidal Ideation and Behavior. MOA: tgts NMDA and 5-HT2a receptors, shown on brain biomarker studies to achieve same beneficial neurochemical changes as SOC, ECT, w/o ECT side effects. Plans to present Ph 2 POC data later this year.
Sector/industry:
Biotech Company
Characteristics:
Clinical Stage
Phase III
Disease Space
Central Nervous System
Industry
Biotechnology
Listing
Private
Market Cap
Private
Website:
Address:
913 North Market Street
Suite 200
Wilmington, DE 19801
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.